Association of albumin to non-high-density lipoprotein cholesterol ratio with mortality in peritoneal dialysis patients

OBJECTIVE

Malnutrition and inflammation are associated with mortality in peritoneal dialysis (PD) patients. Serum albumin and non-high-density lipoprotein cholesterol (non-HDL-C) are independently associated with mortality in PD patients. Combining albumin and non-HDL-C with mortality may be more plausible in clinical practice.

METHODS

This retrospective cohort study included 1954 Chinese PD patients from 1 January 2009 to 31 December 2016. Kaplan-Meier curve was used to determine the relationship between albumin to non-HDL-C ratio and all-cause mortality. Cox regression analysis was applied to assess the independent predictive value while adjusting for confounding factors. Competitive risk analysis was used to examine the effects of other outcomes on all-cause mortality prognosis.

RESULTS

In the 33-month follow-up period, there were 538 all-cause deaths. Kaplan-Meier analysis presented significant differences in all-cause mortality. Multivariate Cox regression showed that the risk of all-cause mortality was lower in the moderate group (9.36-12.79) (HR, 0.731; 95% CI, 0.593-0.902, p = 0.004) and the highest group (>12.79) (HR, 0.705; 95% CI, 0.565-0.879, p = 0.002) compared to the lowest group (≤9.36). Competitive risk analysis revealed significant differences for all-cause mortality (p < 0.001), while there was no statistical significance for other competing events.

CONCLUSIONS

Low albumin to non-HDL-C ratio was associated with a high risk of all-cause mortality in PD patients. It may serve as a potential prognostic biomarker in PD patients.

Nutritional Status in Peritoneal Dialysis: Nutritional Guidelines, Adequacy and the Management of Malnutrition

The positive impact of nutritional status on the health and treatment adequacy of peritoneal dialyzed patients has been well established. Protein intake is an important factor used to stratify malnutrition, with inadequate intake leading to protein-energy wasting during the course of therapy. In this review, we discuss the recommendations made by nephrological societies regarding nutrition in this population of dialysis patients. Special attention is given to the intake of protein, and recommendations on the intake of micronutrients are also discussed. Furthermore, factors that may impair nutritional intake and balance are discussed, with mention of the innovative strategies utilized to combat them. In light of inconsistent recommendations that vary between each respective society, as well as a general lack of concise information, it is our intention to call for further research regarding nutritional recommendations in peritoneal dialysis (PD), as well as to advocate for clear and accessible information for patients.

Nutritional Status of Korean Peritoneal Dialysis Patients

Objectives

To assess the nutritional status of Korean peritoneal dialysis (PD) patients and to compare with data from Western literature, and to elucidate independent factors determining nutritional status and death.

Design

Cross-sectional single-center study.

Setting

Kidney Center, Soon Chun Hyang University Hospital.

Materials

Ninety-eight CAPD patients were included. Of these, 54 patients were male, 32 patients were diabetic, mean age was 47.9 :i: 13.1 years, and mean duration of CAPD was 22.3 :i: 21.6 months. The patients were followed until death, transfer to hemodialysis (HD) or other units, transplantation, or until 3 years had elapsed after the first evaluation.

Methods

Nutritional status was assessed by subjective global assessment (SGA), biochemical and anthropometric measurements, fat-free edema-free (FFEF) body mass by creatinine (Cr) kinetics, protein equivalent of total nitrogen appearance (PNA), and urea kinetic studies.

Results

By SGA score, 53.1% of patients were classified as normal, 44.9% with mild-to-moderate malnutrition, and 2% with severe malnutrition. Patients with malnutrition were significantly older and had higher peritonitis rates, lower serum albumin (Alb), blood urea nitrogen (BUN), serum Cr, FFEF body mass, mid arm muscle circumference, and PNA (p < 0.05). On stepwise multiple regression analysis, the SGA score was negatively correlated with age and peritonitis rate (p < 0.01). At the end of the 3-year follow-up period, 11 patients were still on CAPD, 26 had died, 51 had transferred to HD and 5 to other units, 3 patients had been transplanted, and 2 patients were lost to follow-up. Patients who died during follow-up were older and had higher peritonitis rates and lower total serum protein, Alb, Cr, and FFEF body mass when compared to those who survived (p < 0.05). Independent predictors of death were age, peritonitis rate, and serum Alb (p < 0.01).

Conclusion

Malnutrition was as common in Korean PD patients as reported in the Western literature. Our data suggests that, to prevent malnutrition and early death, it is important to reduce the peritonitis rate, to improve protein intake, and to prescribe an adequate dose of peritoneal dialysis.

Ysis Prescription and Peritoneal Membrane Transport Characteristics on Nutritional Status

These data suggest that dialysis dose is one of the major determinants of protein and energy intake in PD patients and that higher doses of dialysis tend to improve outcome. The data also suggest that with a long time on PD the peritoneal membrane probably has some underlying histological changes that preclude it from optimally responding to injury and may predispose it to irreversible damage. A possible early finding in this case is an increase in peritoneal transport in patients whose transport was initially stable. Peritoneal membrane transport properties are an important determinant of not only dialysis dose, but also nutritional status via both direct and indirect means. It is therefore important to identify the individual patient's peritoneal membrane transport characteristics. These transport characteristics may change over time. High transporters on CAPD represent a unique challenge. They have ultrafiltration problems and a tendency toward protein malnutrition presumably due to increased dialysate protein losses while on CAPD. One must consider that malnutrition in a rapid transporter may be due to the fact that the patient is on the wrong PD therapy. A change to NIPD may rectify some of the biochemical parameters, but these patients may not always improve. Reasons for this occasional lack of improvement are multifactorial, but emphasize our need to look at each patient as an individual and not focus only on laboratory parameters.

A Simple and Fast Method to Estimate Peritoneal Membrane Transport Characteristics Using Dialysate Sodium Concentration

Background

The peritoneal equilibration test (PET) is widely used to classify a patient's peritoneal transport characteristics. However, PET is laborious and the prediction of fluid removal based on PET is generally poor. It is believed that osmosis by glucose occurs partially through transcellular water channels, resulting in sieving of sodium and decrease of dialysate sodium concentration when using hypertonic glucose dialysate.

Objective

In this study, we investigated the possibility of using dialysate sodium concentration to classify the patient's peritoneal transport characteristics.

Methods

A 6-hour dwell study with frequent dialysate and plasma sampling was performed in 46 patients using 2 L of 3.86% glucose dialysate with 1311-albumin as an intraperitoneal volume (IPV) marker. The peritoneal transport of sodium, creatinine, glucose, and fluid was evaluated.

Results

The dialysate sodium concentration at 240 min (ONa240) significantly correlated with O/P creatinine (r = 0.76, p < 0.001) and O/O0 glucose (r = -0.83, p < 0.001) at 240 min of the dwell (better than dialysate sodium concentration at any other time of the dwell). ONa240 also significantly correlated with IPV at 240 min of the dwell (r = -0.61, p < 0.001) (better than O/P creatinine and O/O0 glucose). There were significant correlations between ONa240 and the sodium-sieving coefficient (r= 0.71, p < 0.001) and the diffusive mass transfer coefficient for sodium (r = 0.50, p < 0.001). When using ONa240 to divide the patients into four groups, as in the PET method, no significant difference was found between the two methods.

Conclusion

Using 3.86% glucose solution, ONa240 can be used instead of O/P creatinine to classify patients into different transport groups. ONa240 provides a better prediction of peritoneal fluid transport and reflects both the diffusive and convective transport properties of the membrane. As only one dialysate sample (and no blood sample) is needed, ONa240 may offer important clinical advantages compared with PET.

Management of High Peritoneal Transporters

High transporters on chronic peritoneal dialysis are challenged by increased protein losses, high glucose absorption with associated metabolic abnormalities, and poor ultrafiltration. Furthermore, the relative risk of mortality and technique failure is higher in high transporters than in patients of other transport types. An approach for satisfactory management of such patients on peritoneal dialysis (PD) has not been clearly demonstrated.

Effect of Dialysis Modality and Membrane Transport Characteristics on Dialysate Protein Losses of Patients on Peritoneal Dialysis

Objective

To determine if peritoneal dialysis modality has an impact on protein losses in dialysate.

Design

Retrospective, cross-sectional study.

Patients

190 patients who had selected peritoneal dialysis were classified into one of four transport categories (high, high-average, low-average, or low) based on standard peritoneal equilibration test results. Patients were then assigned to continuous ambulatory peritoneal dialysis (CAPD) or nightly intermittent peritoneal dialysis (NIPD) based on membrane transport characteristics and individual preferences.

Results

Patients with similar membrane transport characteristics had essentially no differences in dialysate protein and albumin losses whether treated with CAPD or NIPD.

Conclusions

Although high transporters may be better managed with short -dwell therapies such as nocturnal intermittent peritoneal dialysis or daily ambulatory peritoneal dialysis, consistent marked decreases in protein losses cannot be cited as a benefit of NIPD over CAPD.

Estimated versus Predicted Creatinine Generation as an Indicator of Compliance with the Prescribed Dose of Continuous Peritoneal Dialysis

The expression (Estimated - Predicted)/Predicted creatinine generation {(E-P)IP} has been proposed as an index of compliance in continuous peritoneal dialysis (CPD). We attempted to define an (E-P)IP value that can be used as a cut-off for non-compliance and to characterize the relation of (E-P)IP to serum albumin. In 324 clearance studies, (E-P)/P had a normal distribution with a mean of +0.094 and an SD of 0.357. In these studies, there was a weak correlation between (E-P)/P and serum albumin (r=0.12, P<0.05), but (E-P)/P was not a predictor of serum albumin by logistic regression. In 34 CPD patients, who had an increase in the dose of CPD resulting in an increase in measured creatinine clearance from 43.8 ± 14.0 to 66.1 ± 17.6 L/1.73 m2 weekly (P<0.001), (E-P)/P increased correspondingly from +0.018 ± 0.284 to +0.153 ± 0.369 (P = 0.018), although all subjects should be in a steady state of creatinine excretion in the second study. The rise in (E-P)/P was statistically significant in the subgroup of 17 subjects who had a decrease in serum albumin, but not in the subgroup of 14 subjects who had an increase in serum albumin from the first to the second clearance study. The (E-P)/P cut-off for a definitive diagnosis of CPD non-compliance may be around +0.400 or +0.500. The findings of this study suggest that non-compliance, as indicated by (E-P)/P, has an adverse effect on serum albumin and that non-compliance increases after a prescribed increase in the dose of CPD.

Higher peritoneal transport status is associated with higher mortality and technique failure in the Australian and New Zealand peritoneal dialysis patient populations

Although early studies observed that peritoneal membrane transport characteristics were determinants of morbidity and mortality in peritoneal dialysis (PD) patients, more recent investigations, such as the Ademex trial, have refuted these findings. The aim of this study was to determine whether baseline peritoneal transport status predicted subsequent survival in Australian and New Zealand PD patients. The study included all adult patients in Australia and New Zealand who commenced PD between April 1, 1999, and March 31, 2004, and had a peritoneal equilibration test (PET) performed within 6 mo of PD commencement. Times to death and death-censored technique failure were examined by Kaplan-Meier analyses and multivariate Cox proportional hazards models. PET measurements were available in 3702 (72%) of the 5170 individuals who began PD treatment in Australia or New Zealand during the study period. In these patients, high transporter status was found to be a significant, independent predictor of death-censored technique failure (adjusted hazard ratio [AHR] 1.23; 95% confidence interval [CI] 1.02 to 1.49; P = 0.03) and mortality (AHR 1.34; 95% CI 1.05 to 1.79, P = 0.02) compared with low-average transport status. High-average transport class was also associated with mortality (AHR 1.21; 95% CI 1.00 to 1.48; P = 0.047) but not death-censored technique failure (AHR 1.04; 95% CI 0.90 to 1.21) compared with low-average transport status. When transport status was alternatively analyzed as a continuous variable, dialysate:plasma creatinine ratio at 4 h was independently predictive of both death-censored technique failure (AHR 1.07; 95% CI 1.01 to 1.295; P = 0.031) and death (AHR 1.09; 95% CI 1.01 to 1.373; P = 0.036 per 0.1 change in dialysate:plasma creatinine). Peritoneal transport rate is a highly significant risk factor for both mortality and death-censored technique failure in the Australian and New Zealand incident PD patient populations.

Adequacy of peritoneal dialysis

The National Kidney Foundation-Dialysis Outcomes Quality Initiatives guidelines have standardized many aspects of treating end-stage renal disease patients with peritoneal dialysis in an attempt to improve overall patient outcome. While recommending certain total solute clearance goals, the guidelines have also pointed out deficiencies in our knowledge base and precipitated many controversies. Some of these controversies have been resolved while others may have been interpreted wrongly, unnecessarily resulting in transfer of patients from peritoneal dialysis to hemodialysis due to "failure to meet adequacy targets" even when doing well clinically. This report reviews the rationale for the original guidelines and their subsequent modification. It also outlines a rational approach toward prescription modification based on peritoneal physiology. Specific solute clearance target goals discussed are the modifications for continuous ambulatory peritoneal dialysis (CAPD) and cycler peritoneal dialysis (CCPD), and a review of what solute clearance targets subsequent guidelines from other countries have used. Some examples are as follows: new guidelines suggest that solute clearance goals for creatine clearance should differ for low and low-average transporters than for high and high-average transporters (weekly clearance of 50 and 60 1/1.73 m(2), respectively) while Kt/V targets remain unchanged. Also discussed is the rationale for having the same target for patients on CCPD with a mid-day exchange as those for patients on CAPD. We are also reminded that solute clearance is only one aspect of "adequate" dialysis-blood pressure and volume control are equally important, and ways to maintain euvolemia and blood pressure control are discussed in the context of prescription management.

Pathogenic effects of a high peritoneal transport rate

Recent studies have shown that patients with high peritoneal transport characteristics have substantially increased morbidity and mortality. This finding is counter-intuitive, since HTs will a priori achieve higher clearances. There are many possible causes: increased protein losses with consequent hypoalbuminemia; poor ultrafiltration capacity causing fluid retention, ventricular hypertrophy and hypertension; increased glucose absorption leading to anorexia, hyperinsulinism, and local AGE formation; and the development of an atherogenic lipid profile. While common pathogenic causes of high peritoneal transport and atherosclerosis have been hypothesized, it is more likely that CAPD as currently practiced is unsuitable for HTs, who should be switched to HD or NIPD. Renal and peritoneal clearances have different clinical effects and should be assessed separately. Current measures of dialysis adequacy, such as total Kt/V, do not therefore describe the patient's clinical situation accurately and are insufficient.

Peritonitis in peritoneal dialysis patients: an overview

The incidence of peritonitis in peritoneal dialysis (PD) patients has decreased as a result of improvements in PD technology. Nevertheless, peritonitis remains a major problem in PD, with a substantial percent of patients developing persistent or relapsing infections. Current treatment guidelines emphasize the use of intraperitoneal antibiotics and once-a-day administration of aminoglycosides and provide indications for removal of the peritoneal catheter. Further clinical studies testing these guidelines are needed. In addition, guidelines for patients on PD treatment modalities other than standard continuous ambulatory peritoneal dialysis (CAPD) need to be developed. Peritonitis may lead to extensive adhesion formation, peritoneal fibrosis of varying severity, permanent loss of peritoneal ultrafiltration, severe malnutrition, sepsis, and death. Special forms of peritonitis requiring great care and further study include those caused by fungi, mycobacteria, and multiple microorganisms, and those developing in HIV-positive PD patients.